

Neurotech

ASX ANNOUNCEMENT

6 February 2019

DESPATCH OF PROSPECTUS TO ELIGIBLE SECURITY HOLDERS

Neurotech International Limited (ASX: NTI) advises that it has despatched the Prospectus and the Entitlement and Acceptance Forms to Eligible Shareholders (as defined in the Prospectus) in accordance with the timetable in the Prospectus announced on 29 January 2019.

For those Eligible Shareholders who wish to participate in the renounceable pro rata offer, you must ensure that by 5.00pm WST on 20 February 2019, either your payment by BPay® is received by BMG, or your Entitlement and Acceptance Form is received by the Company's share registry, being Security Transfer Australia. Further information with respect to participation in the renounceable pro rata offer is set out in the Prospectus.

A copy of the Prospectus can also be located on the Neurotech website at <http://neurotechinternational.com/>.

-ends-

About Neurotech

Neurotech International Limited is a medical device and solutions company incorporated in Australia and operating through its wholly-owned, Malta-based subsidiary AAT Research Limited. Neurotech's primary mission is to improve the lives of people with neurological conditions, with a vision of becoming the global leader in home-use and clinical neurotechnology solutions that are both accessible and affordable. Through flagship device *Mente Autism* and its associated platform, Neurotech is focused on the development and commercialisation of technological solutions for the diagnosis and treatment of such conditions, starting with autism.

Mente Autism is a clinical-quality EEG device that uses neurofeedback technology to help children with ASD. Designed for home use, *Mente Autism* helps relax the minds of children on the spectrum which in turns helps them to focus better and engage positively with their environment.

For more information about Neurotech and *Mente Autism* please visit:

<http://www.neurotechinternational.com>.

<http://www.mentetech.com>.

For more information please contact:

Matthew Wright

matt@nwrcommunications.com.au

Tel: +61 451 896 420

Neurotech International Ltd

ABN 73 610 205 402

Level 14, 225 St Georges Terrace Perth,

Western Australia 6060

www.neurotechinternational.com